Online inquiry

IVTScrip™ mRNA-Anti-MUC1, hPAM4(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8340MR)

This product GTTS-WQ8340MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets MUC1 gene. The antibody can be applied in Pancreatic Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001018016.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4582
UniProt ID P15941
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MUC1, hPAM4(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ8340MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14235MR IVTScrip™ mRNA-Anti-C5, RG-6107(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA RG-6107
GTTS-WQ5814MR IVTScrip™ mRNA-Anti-CD40, CFZ-533(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CFZ-533
GTTS-WQ5260MR IVTScrip™ mRNA-Anti-S, CB-6(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CB-6
GTTS-WQ11201MR IVTScrip™ mRNA-Anti-TNFRSF18, MEDI-1873(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI-1873
GTTS-WQ6624MR IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA DCDS0780A
GTTS-WQ303MR IVTScrip™ mRNA-Anti-IGF1R, 19D12(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 19D12
GTTS-WQ15217MR IVTScrip™ mRNA-Anti-TNFSF13&TNFSF13B, TACI-Fc(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA TACI-Fc
GTTS-WQ5672MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CDX-011
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW